Physician profile
Chandra M Mohan
NPI 1972542736
$2,909.45
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $88.73 · 2021: $369 · 2022: $391 · 2023: $823 · 2024: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $493.69 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $408.09 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $367.75 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.63 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $246.84 | 2019-2023 | Brilinta |
| Pfizer INC. | $166.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $157.17 | 2019-2023 | |
| Boston Scientific Corporation | $116.29 | 2021 | |
| Amarin Pharma, INC. | $96.58 | 2019-2023 | |
| Novo Nordisk INC | $75.36 | 2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $66.08 | 2021-2023 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $55.19 | 2023-2024 | Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $54.69 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $51.06 | 2019-2023 | Camzyos |
| Alnylam Pharmaceuticals INC. | $46.40 | 2023 | Onpattro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $45.90 | 2021-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $38.78 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $35.57 | 2019 | |
| Esperion Therapeutics, INC. | $34.28 | 2022-2024 | Nexletol |
| Astellas Pharma US INC | $29.52 | 2023 | Cresemba |
| Regeneron Healthcare Solutions, INC. | $28.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.